Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Receivables - Other (2018 - 2025)

BioNexus Gene Lab's Receivables - Other history spans 8 years, with the latest figure at $98903.0 for Q3 2025.

  • For Q3 2025, Receivables - Other rose 50.58% year-over-year to $98903.0; the TTM value through Sep 2025 reached $98903.0, up 50.58%, while the annual FY2024 figure was $203660.0, 66.35% up from the prior year.
  • Receivables - Other for Q3 2025 was $98903.0 at BioNexus Gene Lab, down from $151269.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $400830.0 in Q2 2024 and bottomed at $22933.0 in Q1 2021.
  • The 5-year median for Receivables - Other is $79517.0 (2021), against an average of $104137.4.
  • The largest annual shift saw Receivables - Other tumbled 68.26% in 2022 before it skyrocketed 744.19% in 2024.
  • A 5-year view of Receivables - Other shows it stood at $79517.0 in 2021, then crashed by 68.26% to $25240.0 in 2022, then skyrocketed by 385.07% to $122432.0 in 2023, then surged by 66.35% to $203660.0 in 2024, then tumbled by 51.44% to $98903.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Receivables - Other are $98903.0 (Q3 2025), $151269.0 (Q2 2025), and $235727.0 (Q1 2025).